A Phase II study of acute toxicity for Celebrex™ (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: Primary endpoint analysis of RTOG 0128

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 1, 2007, Pages 104-109

  Gaffney, David K ^a   Winter, Kathryn ^b   Dicker, Adam P ^c   Miller, Brigitte ^d   Eifel, Patricia J ^e   Ryu, Janice ^f   Avizonis, Vilija ^g   Fromm, Mitch ^h   Greven, Kathryn ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g LDS HOSPITAL   (United States)

^h AKRON GENERAL MEDICAL CENTER   (United States)

Author keywords

Acute toxicity; Celecoxib; Cervix; Radiation therapy

Indexed keywords

BIOPSY; BONE; CHEMOTHERAPY; HEMODYNAMICS; PATIENT TREATMENT; RADIOTHERAPY;

ACUTE TOXICITY; CELECOXIB; CERVIX; CONCURRENT CHEMORADIATION;

ONCOLOGY;

CELECOXIB; CISPLATIN; FLUOROURACIL; HYDROXYUREA;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; BONE PAIN; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ENDOCRINE DISEASE; EYE DISEASE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HEARING DISORDER; HEART ARRHYTHMIA; HUMAN; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OTOTOXICITY; PAIN; PELVIS FRACTURE; PELVIS RADIOGRAPHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SKIN DISEASE; TOXICITY TESTING; UROGENITAL TRACT DISEASE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; VAGINAL NECROSIS; VISUAL DISORDER;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASM STAGING; PYRAZOLES; RADIOTHERAPY DOSAGE; SULFONAMIDES; UTERINE CERVICAL NEOPLASMS;

EID: 33845682489     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.08.002     Document Type: Article

References (42)

1. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
2. Eifel P.J., Winter K., Morris M., et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22 (2004) 872-880
3. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
4. Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecol Oncol Group and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
5. Peters III W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 (2000) 1606-1613
6. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161
7. Pearcy T., Brundage M., Drouin P., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20 (2002) 966-972
8. Jemal A., Murray T., Ward E., et al. Cancer Statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
9. Parkin D.M., Bray F., Ferlay J., et al. Global Cancer Statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
10. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part 1). J Natl Cancer Inst 90 (1998) 1529-1536
11. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 90 (1998) 1609-1620
12. Ryu H.S., Chang K.H., Yang H.W., et al. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 76 (2000) 320-325
13. Gaffney D.K., Holden J.A., Davis M., et al. Elevated cyclo-oxygenase-2 expression correlate with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 49 (2001) 1213-1217
14. Ferrandina G., Lauriola L., Distefano M.G., et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical patients. J Clin Oncol 20 (2002) 973-981
15. Chen H.H.W., Wu-Chou S., Cheng-Yang C., et al. Increased expression of nitric oxide synthase and Cycloxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 1093-1100
16. Tsujii M., and Du Bois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83 (1995) 493-501
17. Elder D., Halton D., Hague A., et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 3 (1997) 1679-1683
18. Tsujii M., Kawano S., and DuBois R. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94 (1997) 3336-3340
19. Lund E.L., Bastholm L., and Kristjansen P.E. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6 (2000) 971-978
20. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Research 60 (2000) 1306-1311
21. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Research 59 (1999) 3374-3378
22. Williams C.S., Tsujii M., Reese J., et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105 (2000) 1589-1594
23. Chiarugi V., Magnelli L., and Gallo O. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Int J Mol Med 2 (1998) 715-719
24. Milas L., Kishi K., Hunter N., et al. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91 (1999) 1501-1504
25. Gallo O. Re: Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 92 (2000) 346-347
26. Kishi K., Petersen S., Petersen C., et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60 (2000) 1326-1331
27. Steinauer K.K., Gibbs I., Ning S., et al. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 48 (2000) 325-328
28. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
29. Fleming T.R. One-sample multiple testing procedure for Phase II clinical trials. Biometrics 38 (1982) 143-151
30. Available at: http://www.radiotherapy.com/calculate/calc.html. Accessed on February 28, 2006.
31. Liao Z., Komaki R., Milas L., et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11 (2005) 3342-3348 1
32. Cerchietti L.C., Bonomi M.R., Navigante A.H., Castro M.A., Cabalar M.E., and Roth B.M. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol 71 (2005) 73-81
33. Govindan R., McLeod H., and Mantravadi P. Cisplatin Fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology 18 (2004) 18-21
34. Blanke C.D., Mattek N.C., Deloughery T.G., et al. A phase I study of 5-fluorouracil, leucoverin, and celecoxib in patients with incurable colorectal cancer. Prostagland Lipid Mediat 75 (2005) 169-172
35. Milella M., Gelibter A., Di Cosimo S., et al. Pilot study of celecoxib and infusional 5-flouorourcil as second-line treatment for advanced pancreatic carcinoma. Cancer 101 (2004) 133-138
36. Crane C.H., Mason K., Janjan N.A., et al. Initial experience combinig cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol (2003) S81-S84
37. Becerra C.R., Frenkel E.P., Ashfaq R., and Gaynor R.B. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. Int J Cancer 105 (2003) 68-72
38. Pronai L., Hritz I., Molnar B., et al. COX-2-selective inhibitors (COXIBs): gastrointestinal safety. Int J Immunopathol Pharmacol 16 (2003) 23-30
39. Scheiman J.M. Gastroduodenal safety of cyclooxygenase-2 inhibitors. Curr Pharm Des 9 (2003) 2197-2206
40. Stockl K., Cyprien L., and Chang E.Y. Gastrointestinal bleeding rates among managed care patients newly started on cox-2 inhibitors or nonselective NSAIDs. J Manag Care Pharm 11 (2005) 550-558
41. Lanciano R., Calkins A., Bundy B.N., et al. A randomized comparison of weekly cisplatin or protracted venous infusion of Fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol 23 (2005) 8289-8295
42. Torres M., Jhingram A., Bodurka D., Levenback C.F., and Eifel P.J. Concurrent Chemoradiation in the Routine Management of Patients with Cervical Cancer: How does the Experience Compare with Treatment on a Prospective Randomized Trial?. Int J Radiat Oncol Biol Phys 63 Suppl 1 (2005) S95 [Abstract]